The Goldman Sachs Group Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its price target dropped by investment analysts at The Goldman Sachs Group from $178.00 to $100.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 173.82% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Guggenheim dropped their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating on the stock in a research note on Wednesday. Cantor Fitzgerald dropped their target price on Sarepta Therapeutics from $163.00 to $81.00 and set an “overweight” rating on the stock in a research report on Wednesday. Royal Bank of Canada downgraded Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Finally, HC Wainwright cut their price objective on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a “neutral” rating on the stock in a research report on Wednesday. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $131.22.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $36.52 on Wednesday. The stock has a 50 day simple moving average of $68.17 and a 200 day simple moving average of $101.49. Sarepta Therapeutics has a 52-week low of $35.46 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market capitalization of $3.59 billion, a PE ratio of 29.22 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter last year, the company earned $0.73 EPS. The firm’s quarterly revenue was up 80.2% compared to the same quarter last year. Sell-side analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently modified their holdings of the stock. Capital International Investors raised its holdings in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Norges Bank acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $126,315,000. Assenagon Asset Management S.A. grew its position in shares of Sarepta Therapeutics by 438.0% in the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company’s stock valued at $45,477,000 after purchasing an additional 580,123 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 11.1% during the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock worth $348,368,000 after purchasing an additional 285,100 shares during the period. Finally, Vestal Point Capital LP bought a new stake in Sarepta Therapeutics in the 4th quarter valued at $30,398,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.